Jurkat-NFAT-Luc2-CD16-F158-reporter Cell Line

Home » Jurkat-NFAT-Luc2-CD16-F158-reporter Cell Line


CD16, also named FC gamma RIII, is a low or intermediate affinity FC receptor, and has been identified as two receptors including FcγRIIIa (CD16a) and FcγRIIIb (CD16b). It is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody-dependent cytotoxicity and clearance of immune complexes. NFAT proteins, which are expressed in most immune-system cells, play a pivotal role in the transcription of cytokine genes and other genes critical for the immune response. Nuclear factor of activated T cells (NFAT), which is the pharmacological target of immunosuppressants cyclosporine and tacrolimus, has been shown to play an important role not only in T cells (immune system), from which their ame is derived, but also in many biological events. The activity of NFAT proteins is tightly regulated by the calcium/calmodulin-dependent phosphatase calcineurin, a primary target for inhibition by cyclosporin A and FK506. Calcineurin controls the translocation of NFAT proteins from the cytoplasm to the nucleus of activated cells by interacting with an N-terminal regulatory domain conserved in the NFAT family. The DNA-binding domains of NFAT proteins resemble those of Rel-family proteins, and Rel and NFAT proteins show some overlap in their ability to bind to certain regulatory elements in cytokine genes. NFAT is also notable for its ability to bind cooperatively with transcription factors of the AP-1 (Fos/Jun) family to composite NFAT: AP-1 sites, found in the regulatory regions of many genes that are inducibly transcribed by immune-system cells.


Catalog Number:
Cell Line Name:
Jurkat-NFAT-Luc2-CD16-F158-reporter Cell Line
Host Cell Line:
Human Jurkat cell line
Jurkat cell line stable expressing exogenous luciferase gene under the control of NFAT responsive element and human FCGR3A gene
One vial of frozen cells (5×106 per vial)
Stable in culture over a minimum of 10 passages
Drug screening and biological assays
Freeze Medium:
70% RPMI1640+20% FBS+10% DMSO
Propagation Medium:
RPMI1640+10%FBS+300µg/mL Hygromycin B+0.75µg/mL Puromycin
Selection Marker:
Puromycin, HygromycinB
Split saturated culture 1:4-1:6 every 2-3 days; seed out at about 1-3 × 105 cells/mL
37 °C with 5% CO2
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 26 hours
Mycoplasma Status:

Cell Line Generation

Jurkat NFAT-Luc2-CD16a-F158 reporter cell line was generated using lentiviral vector expressing human CD16a sequence.



Cell Resuscitation

1. Prewarm culture medium (RPMI1640 + 10% FBS + 300µg/mL Hygromycin B + 0.75µg/mL Puromycin)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO2 incubator.
8. Split saturated culture 1:4-1:6 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% RPMI-1640 + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
6. Aliquot 1 mL of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage


1. Tada, Minoru, Akiko Ishii-Watabe, Takuo Suzuki, and Nana Kawasaki. 2014. ¡ùDevelopment of a Cell-Based Assay Measuring the Activation of FcÎÛRIIa for the Characterization of Therapeutic Monoclonal Antibodies.¡ì Edited by Paul Zhou. PLoS ONE 9 (4): e95787ÿ89. doi:10.1371/journal.pone.0095787.
2. Koene, H R, M Kleijer, J Algra, D Roos, A E von dem Borne, and M de Haas. 1997. ¡ùFc gammaRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell Fc gammaRIIIa, Independently of the Fc gammaRIIIa-48L/R/H Phenotype..¡ì Blood 90 (3): 1109ÿ14.
3. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997;15:707-47.
4. Kitamura N, Kaminuma O. Isoform-Selective NFAT Inhibitor: Potential Usefulness and Development. Int J Mol Sci. 2021 Mar 8;22(5):2725.
5. Sana I, Mantione ME, Angelillo P, Muzio M. Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies. Front Oncol. 2021 Apr 1;11:651057.
Please enable JavaScript in your browser to complete this form.